Acute Porphyria Drug Database

C01EB10 - Adenosine
Not porphyrinogenic
NP

Rationale
Endogenous nucleoside. No relevant CYP metabolism.
Chemical description
Endogenous nucleoside.
Therapeutic characteristics
Used to stop paroxysmal supraventricular tachycardia.
Metabolism and pharmacokinetics
Adenosine is an endogenous nucleoside. Adenosine is rapidly taken up by most types of cells, including cellular elements of the blood (erythrocytes) and vascular endothelium, where it is rapidly degraded by deamination to inosine and subsequently to hypoxanthine. In addition, adenosine also undergoes phosphorylation to adenosine monophosphate (AMP) inside blood cells. Half time in blood less than 10 seconds. Non-CYP metabolism.
Published experience
Adenosine monophosphate has been proposed and used as a therapeutic agent in the acute porphyrias in the late 60s (Wiontzek, bibliographic data only + Oaks)

References

  1. Scientific articles
  2. Oaks WW, Schultz J, Fleischmajer R. Acute intermittent porphyria. Report of a case treated with adenosine 5 phosphoric acid. Dermatologica 1969; 138(1):10-18. PMID 5764297. #1226
  3. Wiontzek H. [Treatment of acute intermittent prophyria using adenosine monophosphoric acid]. Med Klin 1969; 64(27):1238-1240. PMID 5799781. #1227

Similar drugs
Explore alternative drugs in similar therapeutic classes C01E / C01EB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙